Abstract
The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.
Keywords: Brain, doxorubicin, heart, kidney, liver, therapeutic effects, side effects
Current Medicinal Chemistry
Title: Doxorubicin: The Good, the Bad and the Ugly Effect
Volume: 16 Issue: 25
Author(s): Cristina Carvalho, Renato X. Santos, Susana Cardoso, Sonia Correia, Paulo J. Oliveira, Maria S. Santos and Paula I. Moreira
Affiliation:
Keywords: Brain, doxorubicin, heart, kidney, liver, therapeutic effects, side effects
Abstract: The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers. Despite extensive clinical utilization, the mechanisms of action of DOX remain under intense debate. A growing body of evidence supports the view that this drug can be a double-edge sword. Indeed, injury to nontargeted tissues often complicates cancer treatment by limiting therapeutic dosages of DOX and diminishing the quality of patients life during and after DOX treatment. The literature shows that the heart is a preferential target of DOX toxicity. However, this anticancer drug also affects other organs like the brain, kidney and liver. This review is mainly devoted to discuss the mechanisms underlying not only DOX beneficial effects but also its toxic outcomes. Additionally, clinical studies focusing the therapeutic efficacy and side effects of DOX treatment will be discussed. Finally, some potential strategies to attenuate DOX-induced toxicity will be debated.
Export Options
About this article
Cite this article as:
Carvalho Cristina, Santos X. Renato, Cardoso Susana, Correia Sonia, Oliveira J. Paulo, Santos S. Maria and Moreira I. Paula, Doxorubicin: The Good, the Bad and the Ugly Effect, Current Medicinal Chemistry 2009; 16 (25) . https://dx.doi.org/10.2174/092986709788803312
DOI https://dx.doi.org/10.2174/092986709788803312 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biotechnological Engineering of Heparin/Heparan Sulphate: A Novel Area of Multi-Target Drug Discovery
Current Pharmaceutical Design The Therapeutic Potential of Stem Cells in Amyotrophic Lateral Sclerosis
Current Signal Transduction Therapy HIV-1 Vpr: Regulator of Viral Survival
Current HIV Research Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design The Signaling Function of the IL-13Rα2 Receptor in the Development of Gastrointestinal Fibrosis and Cancer Surveillance
Current Molecular Medicine Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry Structure, Function and Modulation of Chemokine Receptors: Members of the G-Protein-Coupled Receptor Superfamily
Mini-Reviews in Medicinal Chemistry HIV-1 IN Inhibitors: 2010 Update and Perspectives
Current Topics in Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Caveolin Involvement and Modulation in Breast Cancer
Mini-Reviews in Medicinal Chemistry Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets To Enhance or to Inhibit Integrin Function in Angiogenesis, that is the Question
Current Angiogenesis (Discontinued)